Tramadol/Acetaminophen(Ultracet) AS Add-on Therapy in the Treatment of Patients With Ankylosing Spondylitis
Information source: Chung Shan Medical University
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: AS Patients
Intervention: Ultracet (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Chung Shan Medical University
Summary
Ankylosing spondylitis (AS) is a chronic inflammatory arthritis causing back pain, peripheral
arthritis and enthesitis due to genetic background and autoimmunity. Patients with ankylosing
spondylitis usually suffered from chronic pain over spine and peripheral joints since their
second or third decades. It may also cause severe social and psychological burden to
patients and their family.
Exercise and non-steroid anti-inflammatory drugs (NSAID) are the standard first-line
treatments for AS（1）. Only 50% of patients with AS reach the ASAS response criteria（2） in
clinical trials. Patients with severe disease activity should be put on disease-modifying
anti-rheumatic drugs (DMARD), such as sulfasalazine（3） and anti-TNF biological agents. Add-on
of acetaminophen and low dose anti-depressant （4）can slightly improve the response rate.
However, there is no data if tramadol or ultracet can benefit AS.
Tramadol 37. 5 mg/APAP 325 mg combination tablets (ULTRACET®) were effective and safe as
addon therapy with COX-2 NSAID for treatment of osteoarthritis (5) and chronic low back pain
(6).There is no clinical trial regarding tramadol usage in chronic inflammatory arthritis
such as rheumatoid arthritis (RA) or ankylosing spondylitis. It would be important to do a
pilot clinical trial on add-on effect of tramadol to NSAID in patients with AS or RA.
Clinical Details
Official title: Chung Shan Medical University Hospital, Taiwan
Study design: Health Services Research, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome: The primary endpoint of this study is response defined by ASAS Response at 20% level at week 12. These criteria include measures of pain, function, inflammation, and patient global assessment of disease.
Secondary outcome: there is no secondary outcome.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. Diagnosis of AS, as defined by Modified New York Criteria for Ankylosing Spondylitis
2. Active AS, defined by Bath ankylosing spondylitis disease activity index (BASDAI) >3
cm at screening visit.
3. Between 18 and 70 years of age.
Exclusion Criteria:
1. Change of dosage of disease modifying antirheumatic drugs (DMARDs) including
glucocorticoid, hydroxychloroquine, sulphasalazine, and methotrexate within 4 weeks of
baseline.
2. Change of dosage of biological agents within 4 weeks of baseline.
3. Abnormality in chemistry profiles: serum creatinine 3. 0 mg/dl; alanine
aminotransferase (ALT[SGPT]) 5 times the laboratory's upper limit of normal.
4. Pregnant or breast-feeding women.
Locations and Contacts
Chung Shan Medical University Hospital, Taichung 402, Taiwan
Additional Information
Starting date: March 2008
Ending date: December 2008
Last updated: March 28, 2008
|
